Suche Struktur Suche
wx_img
Inquiry Form
  1. Home
  2. TNG348

TNG348

Dose escalation is ongoing in the TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), phase 1/2 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers. The first patient dosed was announced in January 2024.Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

5-Bromo-4-chloro-6-cyclopropylpyrimidine
5-Bromo-4-chloro-6-cyclopropylpyrimidine
CM1051304
27192-21-8
4-Cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
4-Cyclopropyl-6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
CM1075855
2750602-14-1
4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzonitrile
4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzonitrile
CM419198
98298-45-4
[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methanamine
[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methanamine
CM1017820
2098215-73-5